ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Harymeso
|
17K |
6.6M |
4 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
17K
|
6.6M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Harymeso
|
17K |
6.6M |
4 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
17K
|
6.6M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Harymeso
|
17K |
6.6M |
2 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
17K
|
6.6M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Harymeso
|
17K |
6.6M |
3 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
17K
|
6.6M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Harymeso
|
716 |
198K |
7 |
02/12/23 |
02/12/23 |
ASX - By Stock
|
716
|
198K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Harymeso
|
716 |
198K |
2 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
716
|
198K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Harymeso
|
716 |
198K |
6 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
716
|
198K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
Harymeso
|
3.4K |
1.1M |
5 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
Harymeso
|
3.4K |
1.1M |
4 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
|
|
Harymeso
|
275 |
110K |
14 |
25/03/23 |
25/03/23 |
ASX - By Stock
|
275
|
110K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Harymeso
|
17K |
6.6M |
5 |
22/10/22 |
22/10/22 |
ASX - By Stock
|
17K
|
6.6M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Harymeso
|
17K |
6.6M |
0 |
22/10/22 |
22/10/22 |
ASX - By Stock
|
17K
|
6.6M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Harymeso
|
17K |
6.6M |
6 |
10/06/22 |
10/06/22 |
ASX - By Stock
|
17K
|
6.6M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MSB $1 Party
|
|
Harymeso
|
1.1K |
320K |
3 |
04/06/22 |
04/06/22 |
ASX - By Stock
|
1.1K
|
320K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB $1 Party
|
|
Harymeso
|
1.1K |
320K |
0 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
1.1K
|
320K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
MSB $1 Party
|
|
Harymeso
|
1.1K |
320K |
6 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
1.1K
|
320K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
BLA resubmission for children with SR-aGVHD
|
|
Harymeso
|
52 |
22K |
2 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
52
|
22K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MSB Class Action
|
|
Harymeso
|
218 |
67K |
3 |
26/05/22 |
26/05/22 |
ASX - By Stock
|
218
|
67K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
BLA resubmission for children with SR-aGVHD
|
|
Harymeso
|
52 |
22K |
5 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
52
|
22K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
BLA resubmission for children with SR-aGVHD
|
|
Harymeso
|
52 |
22K |
8 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
52
|
22K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
BLA resubmission for children with SR-aGVHD
|
|
Harymeso
|
52 |
22K |
10 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
52
|
22K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
MSB Class Action
|
|
Harymeso
|
218 |
67K |
3 |
23/05/22 |
23/05/22 |
ASX - By Stock
|
218
|
67K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Crohn’s Disease
|
|
Harymeso
|
150 |
54K |
29 |
07/05/22 |
07/05/22 |
ASX - By Stock
|
150
|
54K
|
29
|
|
ASX - By Stock
|
MSB |
Re:
Is Rome burning
|
|
Harymeso
|
90 |
25K |
2 |
12/02/22 |
12/02/22 |
ASX - By Stock
|
90
|
25K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Is Rome burning
|
|
Harymeso
|
90 |
25K |
2 |
12/02/22 |
12/02/22 |
ASX - By Stock
|
90
|
25K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Short Squeeze
|
|
Harymeso
|
505 |
160K |
5 |
10/02/22 |
10/02/22 |
ASX - By Stock
|
505
|
160K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD
|
|
Harymeso
|
211 |
72K |
5 |
01/01/22 |
01/01/22 |
ASX - By Stock
|
211
|
72K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
Harymeso
|
1.0K |
271K |
10 |
25/12/21 |
25/12/21 |
ASX - By Stock
|
1.0K
|
271K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
A Lesson from Osiris
|
|
Harymeso
|
66 |
20K |
20 |
24/12/21 |
24/12/21 |
ASX - By Stock
|
66
|
20K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Greatest Benefit in Diabetics and Ischemics
|
|
Harymeso
|
304 |
94K |
36 |
20/12/21 |
20/12/21 |
ASX - By Stock
|
304
|
94K
|
36
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
Harymeso
|
408 |
123K |
5 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
408
|
123K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Harymeso
|
17K |
6.6M |
8 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
17K
|
6.6M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Moderated
|
|
Harymeso
|
1.5K |
498K |
21 |
07/10/21 |
07/10/21 |
ASX - By Stock
|
1.5K
|
498K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
Harymeso
|
1.0K |
416K |
3 |
28/08/21 |
28/08/21 |
ASX - By Stock
|
1.0K
|
416K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel Controlled Study in Crohns & Ulcerative Colitis
|
|
Harymeso
|
102 |
52K |
3 |
24/10/20 |
24/10/20 |
ASX - By Stock
|
102
|
52K
|
3
|
|
ASX - By Stock
|
MSB Medicine |
Re:
Mesoblast $200 is possible
|
|
Harymeso
|
71 |
58K |
16 |
20/09/20 |
20/09/20 |
ASX - By Stock
|
71
|
58K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID-19/GVHD Update, Quarterly Report and Appendix 4C
|
|
Harymeso
|
248 |
93K |
0 |
18/09/20 |
18/09/20 |
ASX - By Stock
|
248
|
93K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
MSB INFO GOOGLE SHEET - ROLLING UPDATE
|
|
Harymeso
|
106 |
61K |
6 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
106
|
61K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - Aug 2020 on
|
|
Harymeso
|
2.3K |
892K |
19 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
2.3K
|
892K
|
19
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Harymeso
|
23K |
13M |
3 |
05/08/20 |
05/08/20 |
ASX - By Stock
|
23K
|
13M
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Harymeso
|
23K |
13M |
8 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
23K
|
13M
|
8
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Harymeso
|
23K |
13M |
0 |
26/07/20 |
26/07/20 |
ASX - By Stock
|
23K
|
13M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Expands Executive Leadership Team
|
|
Harymeso
|
170 |
79K |
10 |
25/07/20 |
25/07/20 |
ASX - By Stock
|
170
|
79K
|
10
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Harymeso
|
23K |
13M |
9 |
24/07/20 |
24/07/20 |
ASX - By Stock
|
23K
|
13M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Harymeso
|
9.4K |
2.7M |
8 |
23/07/20 |
23/07/20 |
ASX - By Stock
|
9.4K
|
2.7M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 ARDS and ARDS Share Price Scenarios
|
|
Harymeso
|
518 |
262K |
4 |
08/05/20 |
08/05/20 |
ASX - By Stock
|
518
|
262K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Harymeso
|
17K |
6.6M |
0 |
01/05/20 |
01/05/20 |
ASX - By Stock
|
17K
|
6.6M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Harymeso
|
17K |
6.6M |
1 |
01/05/20 |
01/05/20 |
ASX - By Stock
|
17K
|
6.6M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MESO action tonight
|
|
Harymeso
|
3.1K |
1.4M |
3 |
01/05/20 |
01/05/20 |
ASX - By Stock
|
3.1K
|
1.4M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment
|
|
Harymeso
|
296 |
98K |
4 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
296
|
98K
|
4
|
|